Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pancreatic Cancer-Derived Small Extracellular Vesicles Remodel Hepatic Pre-Metastatic Niche via Hybrid Epithelial-Mesenchymal States.

International journal of molecular sciences·2026

Same author

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.

Frontiers in immunology·2026

Same author

Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma.

Journal of experimental & clinical cancer research : CR·2026

Same author

miR-369-3p Modulates LRRK2-Mediated Inflammation and Autophagy in RAW264.7 Macrophages.

International journal of molecular sciences·2026

Same author

Sustainable chemistry and preclinical characterization of RC-106·HCl: A brain-penetrant pan sigma receptor modulator for glioblastoma.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026

Same author

Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast Cancer.

Biomedicines·2026

Same journal

Feasibility of uniportal thoracoscopic sublobar resection without chest tube drainage: a retrospective cohort study.

Frontiers in oncology·2026

Same journal

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China.

Frontiers in oncology·2026

Same journal

Caregiver satisfaction with early integrated palliative care in oncology: secondary outcomes from the PALLiON cluster-RCT.

Frontiers in oncology·2026

Same journal

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report.

Frontiers in oncology·2026

Same journal

The multifaceted roles of mitochondria and their therapeutic transformation: a new perspective on triple-negative breast cancer treatment.

Frontiers in oncology·2026

Same journal

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study.

Frontiers in oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 27, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Circulating hsa-miR-5096 predicts

Martine Bocchini¹, Marcella Tazzari¹, Sara Ravaioli²

¹Immunotherapy, Cell Therapy and Biobank (ITCB), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Frontiers in Oncology

|June 8, 2023

Summary

This summary is machine-generated.

New circulating biomarkers, including hsa-miR-5096, show promise for predicting treatment response and prognosis in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) undergoing Peptide Receptor Radionuclide Therapy (PRRT). These microRNAs correlate with imaging findings and patient outcomes, aiding in GEP-NET management.

Keywords:

PRRT (peptide receptor radionuclide therapy)SSTR2 functional imaging (positron-emission tomography)miRNA – microRNA pancreatic neuroendocrine tumors

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Related Experiment Videos

Last Updated: Jul 27, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Area of Science:

Oncology
Molecular Biology
Biomarker Discovery

Background:

Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare, with limited treatment options for inoperable cases.
Peptide Receptor Radionuclide Therapy (PRRT) shows variable responses, necessitating prognostic biomarkers.
18F-FDG uptake on PET/CT indicates tumor aggressiveness in GEP-NETs.

Purpose of the Study:

To identify circulating microRNAs (miRNAs) associated with 18F-FDG-PET/CT status in GEP-NETs.
To find miRNAs that predict higher risk and lower response to PRRT.
To establish measurable prognostic biomarkers for GEP-NET patient management.

Main Methods:

Whole miRNome Next-Generation Sequencing (NGS) profiling of plasma samples from GEP-NET patients before PRRT.
Differential expression analysis between 18F-FDG positive and negative patient groups.
Validation using Real-Time quantitative PCR, Cox regression for progression-free survival (PFS), and in situ hybridization for miR-protein correlation.

Main Results:

hsa-miR-5096, hsa-let-7i-3p, and hsa-miR-4311 correlated with 18F-FDG-PET/CT in pancreatic NETs (PanNETs).
hsa-miR-5096 predicted 6-month PFS and 12-month Overall Survival post-PRRT, and identified 18F-FDG-PET/CT positive PanNETs with worse prognosis.
hsa-miR-5096 inversely correlated with SSTR2 expression and 68Gallium-DOTATOC uptake, decreasing SSTR2 in vitro.

Conclusions:

hsa-miR-5096 serves as a biomarker for 18F-FDG-PET/CT and an independent predictor of PFS in PanNETs.
Exosomal hsa-miR-5096 may contribute to SSTR2 heterogeneity and PRRT resistance.
Circulating miRNAs offer potential for improved GEP-NET prognostication and treatment stratification.